Camp4 Therapeutics (CAMP) Accumulated Expenses (2023 - 2026)

Camp4 Therapeutics has disclosed Accumulated Expenses across 4 years of filings, most recently posting $4.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.3 million, up 134.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (up 134.06% YoY), and the FY2025 annual result was $5.7 million, up 17.09% from the prior year.
• Accumulated Expenses came in at $4.3 million for Q1 2026 at Camp4 Therapeutics, down from $5.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $5.7 million in Q4 2025 to a low of $1.7 million in Q3 2024.
• The 4-year median for Accumulated Expenses is $3.7 million (2023), against an average of $3.6 million.
• Peak annual rise in Accumulated Expenses reached 138.7% in 2025, while the deepest fall reached 17.09% in 2025.
• Camp4 Therapeutics' Accumulated Expenses stood at $3.3 million in 2023, then surged by 46.37% to $4.8 million in 2024, then grew by 17.09% to $5.7 million in 2025, then retreated by 23.98% to $4.3 million in 2026.
• The last three Accumulated Expenses figures came in at $4.3 million (Q1 2026), $5.7 million (Q4 2025), and $4.1 million (Q3 2025), per Business Quant data.